Why the study?
Although ticagrelor is widely used in cardioprotection, the molecular mechanism of its inhibitory effect on diabetic cardiomyopathy remains poorly elucidated.
Do extracellular vesicles derived from ticagrelor-pretreated cardiomyocytes reduce oxidative and ER stress in hyperglycemic cardiomyocytes?
Population
High-glucose-incubated H9c2 cardiomyocytes mimicking diabetes mellitus
Comparison
EVs from ticagrelor-pretreated H9c2 cells vs EVs from untreated H9c2 cells
Design
In vitro preclinical laboratory study
Authors
Loading...
Hypothesis-generating for ticagrelor-pretreated cardiomyocyte EVs in diabetic cardiomyopathy; prospective human studies needed.
Do extracellular vesicles derived from ticagrelor-pretreated cardiomyocytes reduce oxidative and ER stress in hyperglycemic cardiomyocytes?
Extracellular vesicles derived from ticagrelor-pretreated cardiomyocytes exert cardioprotective effects against diabetic cardiomyopathy by alleviating oxidative and endoplasmic reticulum stress.
Bitirim et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: